Temozolomide Treatment for Pediatric Refractory Anaplastic Ependymoma with Low MGMT Protein Expression.

Abstract

The benefit of postoperative chemotherapy for anaplastic ependymoma remains unknown. We report two pediatric patients with refractory anaplastic ependymoma treated with temozolomide (TMZ). We did not detect O(6) -methylguanine-DNA methyltransferase (MGMT) promoter methylation in tumor samples; however, MGMT protein expression was low. With TMZ treatment, one patient had a 7-month complete remission; the other, stable disease for 15 months. Three other patients did not respond to TMZ; two had high and one low MGMT expression, and two showed no MGMT promoter methylation. These findings suggest that TMZ may be effective for pediatric refractory anaplastic ependymoma with low MGMT protein expression.

• Authors: Kazutoshi Komori, Ryu Yanagisawa, Yosuke Miyairi, Kazuo Sakashita, Masaaki Shiohara, Ikuko Fujihara, Daisuke Morita, Tomohiko Nakamura, Yoshifumi Ogiso, Kenji Sano, Mitsuaki Shirahata, Kohei Fukuoka, Koichi Ichimura, Hiroaki Shigeta
• Journal: Pediatric blood & cancer (Pediatr Blood Cancer) Vol. 63 Issue 1 Pg. 152-5 (Jan 2016) ISSN: 1545-5017 [Electronic] United States
• PMID: 26305586 (Publication Type: Case Reports, Journal Article, Research Support, Non-U.S. Gov't)
• Copyright: © 2015 Wiley Periodicals, Inc.

Chemical References

• Antineoplastic Agents, Alkylating
• Tumor Suppressor Proteins
• Dacarbazine
• DNA Modification Methylases
• MGMT protein, human
• DNA Repair Enzymes
• Temozolomide

Topics

• Antineoplastic Agents, Alkylating (therapeutic use)
• Brain Neoplasms (chemistry, drug therapy)
• Child, Preschool
• DNA Modification Methylases (analysis)
• DNA Repair Enzymes (analysis)
• Dacarbazine (analogs & derivatives, therapeutic use)
• Ependymoma (chemistry, drug therapy)
• Female
• Humans
• Immunohistochemistry
• Infant
• Male
• Temozolomide
• Tumor Suppressor Proteins (analysis)